Research progress in the treatment of acute radiation sickness with thrombopoietin receptor agonist romiplostim

VernacularTitle:血小板生成素受体激动剂罗米司亭治疗急性放射病研究进展
Author: Xin YANG ^{1
,

2} ; Shuang XING ; Zuyin YU
Author Information

1. 蚌埠医科大学药学院,安徽蚌埠 233030
2. 军事科学院军事医学研究院,北京 100850
Keywords: romiplostim; acute radiation sickness; ionizing radiation; hematopoietic injury
From: Military Medical Sciences 2024;48(11):858-862
CountryChina
Language:Chinese
Abstract: Acute radiation sickness(ARS)is a systemic syndrome caused by exposure to large doses of radiation in a single or short period of time.Hematopoietic tissue injury is the basic injury in case of acute radiation sickness.Romiplostim(RP)is a thrombopoietin receptor agonist that promotes platelet production by stimulating bone marrow megakaryocytes.In recent years,studies have shown that RP has a significant effect on acute radiation sickness,and has been approved by the United States Food and Drug Administration(FDA)for the treatment of bone marrow acute radiation sickness.In this paper,the recent research progress in the treatment of acute radiation sickness with romiplostim is reviewed.